# The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

> **NCT06495541** · NA · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Breast Cancer
- RWS
- Pyrotinib

## Interventions

- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT06495541
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06495541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06495541, "The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06495541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*